Part 3 · Chapter 3.3

Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the second-largest receptor family after GPCRs. They transduce growth-factor and cytokine signals through ligand-induced dimerisation, trans-autophosphorylation, and SH2-domain-mediated recruitment of downstream effectors — most famously the Ras–Raf–MEK–ERK MAPK cascade. 58 RTK genes in humans; drug targets include EGFR (lung cancer), HER2 (breast), VEGFR (anti-angiogenic), KIT (GIST).

1. RTK Activation Mechanism

RTKs are single-pass transmembrane proteins with an intracellular tyrosine-kinase domain. Ligand binding drives dimerisation (occasionally higher oligomers for some IR/IGFR); dimer brings kinase domains into proximity; each phosphorylates tyrosines on the other (trans-autophosphorylation). Phosphotyrosines recruit SH2-domain adaptors (Grb2, SHC, PI3K-p85), building a membrane-localised signalling complex.

2. The MAPK Cascade

Ras activation initiates the canonical Raf → MEK → ERK cascade:

\[ \text{Ras-GTP} \;\to\; \text{Raf} \;\to\; \text{MEK} \;\to\; \text{ERK} \;\to\; \text{nuclear TFs} \]

Huang & Ferrell 1996 showed this triple-kinase architecture produces ultrasensitivity: a graded input converts to a switch-like output. Three sequential steps with moderate Hill coefficients compound into an effective Hill coefficient of n ∼ 5 — the cellular equivalent of a digital decision gate between quiescence and mitosis.

Simulation: MAPK Ultrasensitivity

Python

script.py31 lines

import numpy as np, matplotlib
matplotlib.use('Agg')
import matplotlib.pyplot as plt

# MAPK cascade kinetics: Huang-Ferrell 1996 ultrasensitivity
EGF = np.logspace(-2, 2, 100)
# Each MAPK layer acts as a low-pass + steep transition
# Three sequential Hill curves with increasing n
def hill(x, K, n): return x**n / (K**n + x**n)
R_active = hill(EGF, 1, 1)      # receptor ~ linear
Ras = hill(R_active, 0.3, 2)    # moderate
MEK = hill(Ras, 0.3, 3)         # sharp
ERK = hill(MEK, 0.3, 5)         # ultrasensitive switch

fig, ax = plt.subplots(figsize=(11, 6), facecolor='#0a0f1e')
ax.set_facecolor('#111e2f'); ax.tick_params(colors='#bae6fd')
for s in ax.spines.values(): s.set_color('#334155')
ax.semilogx(EGF, R_active, color='#60a5fa', lw=2.5, label='Receptor (n=1)')
ax.semilogx(EGF, Ras, color='#34d399', lw=2.5, label='Ras (n=2)')
ax.semilogx(EGF, MEK, color='#fbbf24', lw=2.5, label='MEK (n=3)')
ax.semilogx(EGF, ERK, color='#f87171', lw=2.5, label='ERK (n=5)')
ax.set_xlabel('EGF dose (relative)', color='#bae6fd')
ax.set_ylabel('Fraction active', color='#bae6fd')
ax.set_title('MAPK cascade: sequential Hill n amplifies to switch',
             color='#67e8f9', fontweight='bold')
ax.legend(facecolor='#1e293b', edgecolor='#334155', labelcolor='#cbd5e1')
ax.grid(True, color='#334155', alpha=0.3)
plt.tight_layout()
plt.savefig('output.png', dpi=120, bbox_inches='tight', facecolor='#0a0f1e')
print('Huang-Ferrell: 3 sequential MAPK levels convert graded input to switch output')
print('ERK activation at EGF saturation is Boolean: quiescent -> mitotic decision')

Click Run to execute the Python code

Code will be executed with Python 3 on the server

3. JAK-STAT & Cytokine Receptors

Cytokine receptors (IL-6, interferon, leptin, erythropoietin) lack intrinsic kinase activity but associate with soluble JAK kinases. Ligand binding brings two JAKs together; cross-phosphorylation activates them, and phosphorylated JAKs recruit STAT transcription factors. Dimerised STATs translocate to nucleus and drive target transcription. JAK inhibitors (tofacitinib, ruxolitinib) are major immunology drugs.

4. Clinical Relevance

Activating mutations in RTKs drive many cancers: EGFR exon 19/21 mutations (NSCLC), HER2 amplification (breast), BCR-ABL fusion (CML). Tyrosine-kinase inhibitors (TKIs) — imatinib, gefitinib, erlotinib, crizotinib — transformed oncology from toxic chemotherapy to targeted therapy. BCR-ABL inhibition by imatinib made chronic-phase CML a manageable chronic disease.

Key References

• Lemmon, M. A. & Schlessinger, J. (2010). “Cell signaling by receptor tyrosine kinases.” Cell, 141, 1117–1134.

• Huang, C.-Y. & Ferrell, J. E. (1996). “Ultrasensitivity in the MAPK cascade.” Proc. Natl. Acad. Sci., 93, 10078–10083.

• Druker, B. J. et al. (2001). “Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in CML.” N. Engl. J. Med., 344, 1031–1037.

← 3.2 G-Protein 3.4 Second Messengers →